<DOC>
	<DOC>NCT01087203</DOC>
	<brief_summary>The purpose of this study is to determine the effectiveness and safety of the investigational drug, tanezumab, in adult patients with painful diabetic peripheral neuropathy.</brief_summary>
	<brief_title>A Study Of The Analgesic (Pain-Relief) Effects Of Tanezumab In Adult Patients With Diabetic Peripheral Neuropathy</brief_title>
	<detailed_description>This study was terminated on 18 November 2010 following a US FDA clinical hold for the tanezumab diabetic peripheral neuropathy clinical study which halted dosing and enrollment of patients on 19 July 2010 for potential safety issues.</detailed_description>
	<mesh_term>Peripheral Nervous System Diseases</mesh_term>
	<mesh_term>Diabetic Neuropathies</mesh_term>
	<mesh_term>Analgesics</mesh_term>
	<criteria>Diagnosis of diabetes mellitus (high blood sugar) with HbA1c levels of ≤11% at Screening, and on a stable antidiabetic medication regimen for the 30 days prior to randomization. Diagnosis of diabetic peripheral neuropathy pain in the legs or feet with decreased sensation in the feet or decreased/absent ankle jerk/ reflexes. Presence of ongoing pain due to diabetic peripheral neuropathy for at least 3 months. A pain score of greater than or equal to (≥) 4 for from diabetic peripheral neuropathy on the Numerical Rating Scale (NRS), a 11point scale with 0 meaning no pain and 10 meaning worst pain at Screening. Be willing to stop all pain medications for diabetic peripheral neuropathy except for the limited use of acetaminophen (Tylenol) or ibuprofenlike (Motrin) medications between Screening and Baseline and not use prohibited pain medications throughout the duration of the study except as permitted by the study guidelines. Painful neuropathies other than diabetic peripheral neuropathy. Other types of diabetic neuropathies. Patients with a past history of carpal tunnel syndrome (CTS) with signs or symptoms of CTS in the one year prior to Screening are not eligible for participation. Patients with fibromyalgia, regional pain caused by lumbar or cervical compression with radiculopathy or other moderate to severe pain. Patients with a present (current) history of sciatica are not eligible for participation. The presence of pain conditions that cannot be distinguished from diabetic peripheral neuropathy such as peripheral vascular disease. Amputations dues to diabetes. Patient with any clinically significant medical condition or laboratory abnormalities. History, diagnosis, or signs and symptoms of clinically significant neurological diseases (such as Alzheimer's disease, head trauma, epilepsy or stroke). History, diagnosis, or signs and symptoms of clinically significant psychiatric diseases (such as bipolar disorder or schizophrenia). History of known alcohol, analgesic or drug abuse within 2 years of Screening. Pregnant women, lactating mothers, women suspected of being pregnant, and women who wish to be pregnant during the course of clinical study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>diabetic peripheral neuropathy</keyword>
	<keyword>tanezumab</keyword>
	<keyword>diabetic neuropathies</keyword>
	<keyword>diabetic polyneuropathy</keyword>
	<keyword>diabetic neuropathy painful</keyword>
</DOC>